MedPath

Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents

Phase 4
Conditions
Coronary Artery Disease
Interventions
Device: Promus Element, Boston Scientific Corporation
Device: Nobori, Terumo Corporation (Japan)
Registration Number
NCT01268371
Lead Sponsor
Ajou University School of Medicine
Brief Summary

To compare the safety and efficacy of coronary stenting with everolimus-eluting stent (Promus Element®) and biolimus-eluting stent with biodegradable polymer (Nobori®)

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1462
Inclusion Criteria
  • Significant coronary artery stenosis (> 50% by visual estimate)
  • Stable angina, unstable angina, Non-ST elevation myocardial infarction (NSTEMI) and documented silent ischemia
  • Patients eligible for intracoronary stenting
  • age ≥ 20 years old
Exclusion Criteria
  • ST segment elevation myocardial infarction (within 24 hours)
  • Low ejection fraction (< 25%)
  • Cardiogenic shock
  • History of bleeding diathesis or known coagulopathy
  • Limited life-expectancy (less than 1 year) due to combined serious disease
  • Contraindication to heparin, sirolimus, everolimus and biolimus
  • Contraindication to aspirin and clopidogrel
  • Pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Promus ElementPromus Element, Boston Scientific CorporationEverolimus-eluting stent
NoboriNobori, Terumo Corporation (Japan)Biolimus-eluting stent with biodegradable polymer
Primary Outcome Measures
NameTimeMethod
The Number of Participants with Majour Adverse Cardiac Events (composite of death, myocardial infarction, target vessel revascularization and stent thrombosis1 year after index procedure
Secondary Outcome Measures
NameTimeMethod
Myocardial infarction (Q wave and non-Q wave)1 to 2 years after index procedure
Target vessel revascularization (ischemia- and clinically-driven)1 to 2 years after index procedure
The number of participants with majour adverse cardiac events (composite of death, myocardial infarction, target vessel revascularization and stent thrombosis2 years after index procedure
Death (all-cause and cardiac)1 to 2 years after index procedure
Target lesion revascularization (ischemia- and clinically-driven)1 to 2 years after index procedure
Stent thrombosis1 to 2 years after index procedure
In-stent and in-segment late loss at 1 year angiographic follow-up1 year after index procedure
In-stent and in-segment restenosis at 1 year angiographic follow-up1 year after index procedure
Incidence and angiographic pattern of restenosis at 1 year angiographic follow-up1 year after index procedure
The incidence of Procedural successindex procedure (day 0)
The number of participants with death and myocardial infarction1 to 2 years after index procedure

Trial Locations

Locations (26)

St. Carollo Hospital

🇰🇷

Suncheon, Korea, Republic of

Yonsei University Gangnam Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Daegu Catholic University Medical Center

🇰🇷

Daegu, Korea, Republic of

Pusan National University Yangsan Hospital

🇰🇷

Yangsan, Korea, Republic of

Hallym University Sacred Heart Hospital

🇰🇷

Anyang, Korea, Republic of

Inje University ilsan Paik Hospital

🇰🇷

Ilsan, Korea, Republic of

Hallym University Kangdong Sacred Heart Hospital

🇰🇷

Seoul, Korea, Republic of

The Catholic University of Korea Seoul ST. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Hallym University Hankang Sacred Heart Hospital

🇰🇷

Seoul, Korea, Republic of

Soon Chun Hyang University Hospital Cheonan

🇰🇷

Cheonan, Korea, Republic of

Chungnam National University Hospital

🇰🇷

Daejon, Korea, Republic of

Sejong Hospital

🇰🇷

Bucheon, Korea, Republic of

Soon Chun Hyang University Hospital Bucheon

🇰🇷

Bucheon, Korea, Republic of

Cheju Halla General Hospital

🇰🇷

Cheju, Korea, Republic of

Catholic University ST. Vincent's Hospital

🇰🇷

Suwon, Korea, Republic of

Ulsan University Hospital

🇰🇷

Ulsan, Korea, Republic of

Gachon University Gil Hospital

🇰🇷

Incheon, Korea, Republic of

Kangwon National University Hospital

🇰🇷

Chuncheon, Korea, Republic of

Keimyung University Dongsan Hospital

🇰🇷

Daegu, Korea, Republic of

Gangneung Asan Hospital

🇰🇷

Gangneung, Korea, Republic of

Pusan National University Hospital

🇰🇷

Pusan, Korea, Republic of

Konyang University Hospital

🇰🇷

Daejon, Korea, Republic of

Chonnam National University Hospital

🇰🇷

Gwangju, Korea, Republic of

Kyunghee University Medical Center

🇰🇷

Seoul, Korea, Republic of

Ajou University Medical Center

🇰🇷

Suwon, Korea, Republic of

Yonsei University Wonju College of Medicine Wonju Christion Hospital

🇰🇷

Wonju, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath